


HOSTED BY



ELSEVIER

Contents lists available at ScienceDirect

## The Egyptian Journal of Medical Human Genetics

journal homepage: [www.sciencedirect.com](http://www.sciencedirect.com)

## Original article

Association of genetic polymorphisms of *PON1* and *CETP* with the presence of metabolic syndrome; the effects of genotypes on their serum activity and concentrationsBehdokht Fathi Dizaji<sup>a</sup>, Mahdi Rivandi<sup>b,c</sup>, Ali Javandoost<sup>d</sup>, Maryam Saberi Karimian<sup>b</sup>, Atena Raei<sup>d</sup>, Amirhossein Sahebkar<sup>e</sup>, Gordon Ferns<sup>f</sup>, Majid Ghayour Mobarhan<sup>g,\*</sup>, Alireza Pasdar<sup>b,h,i,\*</sup><sup>a</sup> Department of Medical Genetics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran<sup>b</sup> Department of Modern Sciences & Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran<sup>c</sup> Student Research Committee, Department of Modern Sciences & Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran<sup>d</sup> Department of Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran<sup>e</sup> Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran<sup>f</sup> Brighton & Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex BN1 9PH, UK<sup>g</sup> Biochemistry of Nutrition Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran<sup>h</sup> Division of Applied Medicine, Medical School, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK<sup>i</sup> Medical Genetics Research Centre, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

## ARTICLE INFO

## Article history:

Received 8 November 2017

Accepted 24 December 2017

Available online 17 January 2018

## Keywords:

Metabolic syndrome

*PON1* gene*CETP* gene

Single nucleotide polymorphism (SNP)

## ABSTRACT

**Background:** The Metabolic syndrome (MetS) is associated with an increased risk of cardiovascular disease and type 2 diabetes. *PON1* and *CETP* genes may be involved in the pathogenesis of lipid metabolism and thus MetS. Several single nucleotide polymorphisms of genes were demonstrated to affect their function. Curcumin (diferuloylmethane) is a yellow pigment of turmeric that has shown numerous pharmacological activity against obesity and related conditions through anti-oxidant/anti-inflammatory properties.

**Objective:** We aimed to assess the association of these polymorphisms with metabolic syndrome and to investigate if these genetic variants were associated with an altered activity of *PON1* and the protein levels of *CETP* at base line and after Curcumin supplementation.

**Methods:** The genotypes of *PON1* and *CETP* polymorphisms were determined in 81 patients with MetS and 100 healthy individuals using ARMS-PCR and PCR-RFLP techniques.

**Results:** Individuals with different genotypes of the *PON1* rs662, rs854560 and rs705379 polymorphisms did not differ with paraoxonase activity and *CETP* serum protein concentrations, either at baseline, or after intervention. Individuals with different *PON1* rs854560 genotypes differ significantly in serum arylesterase activities ( $p = .037$ ). There were statistically significant differences in genotype frequencies between cases and controls for *CETP* rs5882 genotypes ( $p$ -value = .034) but not in genotype frequencies and haplotypes for *PON1* studied polymorphisms ( $p$ -value < .05). The odds ratio for *CETP* rs5882 was statistically significant using a dominant model. OR (95% CI) = 0.48 (0.25–0.92),  $p$ -value = .029.

**Conclusions:** There were no associations between the *PON1* polymorphisms, or haplotypes with MetS. There was an association between *CETP*rs5882 and metabolic syndrome. AA genotype of *CETP*rs5882 appeared to be protective against MetS in our studied population. There were no association between the *PON1* and *CETP* polymorphisms with *PON1* enzymatic activities and *CETP* protein levels at base line and after curcumin supplementation.

© 2018 Production and hosting by Elsevier B.V. on behalf of Ain Shams University. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Peer review under responsibility of Ain Shams University.

\* Corresponding authors at: Molecular Medicine Group, Department of Modern Sciences and Technologies, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran (A. Pasdar). Cardiovascular Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran (M.G. Mobarhan).

E-mail addresses: [GhayourM@mums.ac.ir](mailto:GhayourM@mums.ac.ir) (M.G. Mobarhan), [a.pasdar@abdn.ac.uk](mailto:a.pasdar@abdn.ac.uk), [Pasdara@mums.ac.ir](mailto:Pasdara@mums.ac.ir) (A. Pasdar).

## 1. Introduction

Metabolic syndrome (MetS) is defined by a clustering of cardiovascular risk factors including: central obesity, insulin resistance, hypertension and atherogenic dyslipidemia, and is associated with a greater risk of type 2 diabetes and cardiovascular disease (CVD) [1,2].

<https://doi.org/10.1016/j.ejmhg.2017.12.001>

1110-8630/© 2018 Production and hosting by Elsevier B.V. on behalf of Ain Shams University.

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

The prevalence of (MetS) is increasing globally, and in Iran it has one of the highest occurrences worldwide. In the adult population, a prevalence of 30% in Tehran and 45% in Khorasan province has been reported [3].

MetS is a multifactorial disorder in which environmental factors as well as genetic factors play a role [4]. The heritability of MetS has been estimated to be 24–30% [5,6].

Two genes, *PON1* and *CETP* take part in pathways that may be involved in the pathogenesis of MetS [7,8].

Paraoxonase 1 (*PON1*) is involved in the antioxidant defence system and while it has major catalytic paraoxonase/arylesterase activities, its physiological substrates are lactones, oxidized-LDL and homocysteine thiolactone, and hence it may protect against cardiovascular diseases (CVD) [7].

The paraoxonase gene cluster comprises three members *PON1-PON2-PON3* that are located on chromosome 7q21.3 [9]. More than 160 polymorphisms (SNPs) have been reported for the *PON1* gene [10], of which the Q192R, L55M, -108C/T have been shown to be associated with serum enzyme protein concentrations and activity. The Q192R and L55M SNPs are in coding regions and cause an amino acid substitution. -108C/T is in the promoter of the gene and affects its expression [7,11,12].

Studies have demonstrated that the serum activity and concentrations of *PON1* are reduced in conditions in which oxidative stress may be a contributory factor, such as CVD, Alzheimer, MetS, aging and higher levels of *PON1* may be protective against these diseases [13].

Cholesterol ester transfer protein (*CETP*) is a plasma glycoprotein expressed in the liver and secreted into the plasma. The *CETP* gene is located on the chromosome 16q13, has 16 exons and is 26 kb long [14].

*CETP* is involved in the exchange of TG on LDL with cholesteryl esters on HDL, and results in HDL particles that can be degraded by hepatic lipase. *CETP* is also involved in reverse cholesterol transport (RCT) and therefore it is not completely clear whether increasing *CETP* activity would be pro- or anti-atherogenic [8,15–17].

Several SNPs of the *CETP* gene have been identified which the I405V causes an isoleucine for valine substitution. In genome wide association studies (GWAS) it has been found that variation at the *CETP* gene locus is associated with low levels of HDL-c and is related to CVD [18].

Curcumin is a polyphenolic compound derived from turmeric that has anti-inflammatory and antioxidant properties. It has poor bioavailability when given orally, but this can be improved by using a phytosomal complex [19,20]. Phytosomes are chemical complexes which are synthesized by one or two moles of synthetic or natural phospholipids mainly phosphatidylcholine, and one mole of botanical extracts [21].

The aim of this study was to investigate the association between *PON1* and *CETP* genetic polymorphisms and the presence of MetS. In addition, the associations of *PON1* and *CETP* genetic polymorphisms with *PON1* enzymatic activities and the serum concentrations of *CETP* protein in response to curcumin supplementation was studied in the context of a clinical trial in MetS patients.

## 2. Subjects and methods

Blood samples of individuals with MetS were obtained from subjects who were randomised for a clinical trial study with registration number of IRCT2014052014521N3 that examined the efficacy of phytosomal curcumin in MetS patients. Volunteers referred to the Nutrition Clinic of Qaem hospital in Mashhad city between September to November 2015. A diagnosis of MetS was made using IDF criteria [1]. All participants gave their written informed consent to participate in this study, which received the

approval of the Research Council of the Mashhad University of Medical Science. Patients with kidney disease, systemic lupus erythematosus (SLE), pregnant women and patients taking anti hyperlipidemic, or anti hyperglycaemic drugs during the previous 6 months were excluded from the study. The subjects were randomly allocated to three subgroups receiving either: 1- phytosomal Curcumin, 2-curcumin and 3-placebo. Then for this study, groups 1 and 3 were selected as cases (n = 81 of 120 subjects) of the randomised clinical trial study. The work has been carried out in accordance of the Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments in humans with IR.MUMS.REC.1394.209 reference number. In addition, 100 healthy individuals, sex and age matched with cases were selected as the control group to conduct this case control study. MetS patients were treated either with phytosomal curcumin (1mg per day; group1)/plain curcumin (1g per day-group2) or placebo (group3) for six weeks. Twenty ml of blood was taken before and after the intervention period. Anthropometric, demographic and biochemical parameters were recorded for each subject before and after the intervention period. The paraoxonase/arylesterase activity of paraoxonase 1 enzyme and levels of *CETP* protein before and after intervention were assessed in all MetS patients. The relationship between the *PON1* rs662, rs854560 and rs705379 genotypes and serum enzymes paraoxonase/arylesterase activity, and the *CETP*rs5882 genotypes with serum protein concentrations were determined before and after intervention.

### 2.1. DNA extraction

DNA was extracted using a DNA extraction kit (Pars tous, Iran) according to the manufacturer's instruction and the integrity of extracted DNA were examined by electrophoresis technique.

### 2.2. Genotyping

ARMS-PCR and PCR-RFLP were used to identify the various SNP genotypes, and sequencing was performed to confirm the validity of these techniques.

#### 2.2.1. ARMS-PCR

ARMS-PCR with 2 different sets of primers was designed to determine genotypes of *PON1* rs662 and *CETP* rs5882 in patients and controls. Three primers were used to determine the alleles of polymorphism and a pair of primers to amplify an internal control band. Primers to amplify *PON1* rs662 were 5'-ACTATTTTCTTGACCCCTACTTATG-3' and 5'-CTATTTTCTTGACCCCTACTTCA-3' and 5'-AGTTCACACTTGCCATCGG-3' with an annealing temperature of 62<sup>o</sup>c for 35 cycles yielding a 158 bp fragment for allele A and 159 bp for allele G. Primers to amplify *CETP*rs5882 were 5'-GCAGAGCAGCTCCGAGTACG -3', 5'-GCAGAGCAGCTCCGAGTACA -3' and 5'-CCGCGGGTGGCAAAGATAA-3' with an annealing temperature of 63<sup>o</sup>c for 35 cycles yielding a 311 bp fragment for both alleles A and G. We also designed a pair of primers to replicate a 408 bp of *HBB* gene as an internal control band to check the accuracy of PCR reactions. The primers were 5'-GAAGTCTGCCGTACTGCC-3' and 5'-GATCCACGTGCAGCTTGCA-3'. The PCR reaction was carried out for *PON1* rs662 in a total volume of 15 µl using Taq DNA Polymerase 2x Master Mix Red (Ampliqon) and 0.5 pmol/µl of allele specific primers and 0.3 pmol/µl of internal control primers and for *CETP*rs5882 the total volume was 15 µl and the same PCR conditions as *PON1* rs662 but with a greater concentration of template DNA.

#### 2.2.2. PCR-RFLP

The *PON1* rs854560 and rs705379 SNPs each was genotyped separately by PCR amplification and restriction digest. Primers

used for rs854560 were designed including 5'-ATGGGTATACA GAAAGCCTAAGTGA-3' and 5'-GGAAAAGCTCTAGTCCATCAA-3' with an annealing temperature of 61 °C for 1 min for 35 cycles. The 403 bp fragment was digested with *Hin1III* yielded 129 + 274 bp bands in presence of a T allele. Nevertheless, primers used for rs705379 were 5'-TGACGCCGAGCCCTGCTGGGGCAGCGCCGATTGGCCCG CCGC-3' and 5'-GACCGAAGCCACGCCCTCTGTGCACC-3' with an annealing temperature of 71°C for 1 min and 35 cycles [22]. The digested bands with *BstUI* were 42 and 67 bp in presence of C allele. The PCR product size was 109 bp. We also used a sequencing technique and read the sequence of 14 samples of all 4 SNPs to confirm the results of our genotyping. All results were the same as previously determined.

### 2.3. Statistical analysis

The data were analysed by using SPSS version 16. Statistical significance was considered at a  $P < .05$ . Discrete data were analysed by Chi-square test. Continuous data was assessed for normality using the Kolmogorov-Smirnov test. Independent sample T-Test and One – Way ANOVA tests were used to evaluate normally distributed variables and were expressed as means with their standard deviation. Mann-Whitney and Kruskal-Wallis tests were used for non-normally distributed variables and are expressed as medians and interquartile ranges. Hardy-Weinberg analysis were performed to assess the genotype distributions. Case-control genotypic and allelic distribution were calculated using  $\chi^2$  statistics. The Odds ratio (OR) with 95% confidence intervals (95% CI) was estimated in dominant, recessive and multiplicative models for all SNPs after determining risky alleles. The Bonferonni correction was made for multiple testing. Haplotype analysis was conducted by PHASE software (<http://stephenslab.uchicago.edu/software.html#phase>).

## 3. Results

Anthropometric, demographic and biochemical parameters of the studied population are shown in Table 1. There was no difference in age between cases and controls as they were matched for this. Other parameters as expected were higher in patients, except for serum HDL-c that was lower in patients (Tables 2–5)

Statistical significance level  $P$ -value  $< .05$ . Normally distributed variables expressed as mean  $\pm$  SD. Non-normally distributed variables are expressed as median and interquartile range.

HDL-C: high-density lipoprotein cholesterol, WC: waist circumference, SBP systolic blood pressure, DBP diastolic blood pressure, TG: triglycerides, FBG: fasting blood glucose.

### 3.1. Relationship of PON1 polymorphisms with Paraoxonase/ Arylesterase activity and CETP polymorphism with protein level

The relationship of *PON1* rs662, rs854560 and rs705379 genotypes with enzyme paraoxonase activity and *CETP*5882 genotypes

**Table 1**  
Anthropometric, demographic and biochemical parameters of the study subjects.

Variable	Case	Control	P-value
BMI (kg/m <sup>2</sup> )	26.47 $\pm$ 4.42	30.82 $\pm$ 4.79	<.05
Cholesteryl(mg/dl)	175.37 $\pm$ 3.04	240.79 $\pm$ 5.31	<.05
HDL-C (mg/dl)	48.71 $\pm$ 10.7	52.09 $\pm$ 11.92	<.05
Age(year)	42(16.25)	38(4.75)	<b>0.781</b>
Weight(kg)	79.60(16.90)	67(14.75)	<.05
WC(cm)	101(11)	88(13.75)	<.05
SBP(mmHg)	122(18)	110.67(14.92)	<.05
DBP(mmHg)	79(9)	75(10)	<.05
TG(mg/dl)	149.5(101.5)	87.5(46)	<.05
FBS(mg/dl)	95(26)	80(16.75)	<.05

**Table 2**

The relationship of *PON1* and *CETP* polymorphisms with Paraoxonase activity and *CETP* protein levels.

PON1	Genotypes	Mean $\pm$ SD	P-value
rs662	AA	0.508 $\pm$ 0.176	.775
	AG	0.538 $\pm$ 0.167	
	GG	0.535 $\pm$ 0.184	
Total	75	0.527 $\pm$ 0.171	
rs854560	AA	0.513 $\pm$ 0.16	.767
	AT	0.531 $\pm$ 0.16	
	TT	0.566 $\pm$ 0.22	
Total	76	0.528 $\pm$ 0.17	
rs705379	CC	0.503 $\pm$ 0.17	.385
	CT	0.515 $\pm$ 0.15	
	TT	0.577 $\pm$ 0.19	
Total	75	0.527 $\pm$ 0.17	
CETPrs5882	AA	0.4338 $\pm$ 0.12	.842
	AG	0.4622 $\pm$ 0.15	
	GG	0.4365 $\pm$ 0.15	
Total	43	0.4525 $\pm$ 0.14	

The results of paraoxonase1 activity before intervention are shown that they were not statistically significant. The results of *CETP* protein concentrations before intervention are demonstrate that they are not statistically significant. Comparisons are performed using one-way ANOVA test. Statistical significance level  $P$ -value  $< .05$ .

with protein level before and after intervention were not significant. The differences of arylesterase activities between genotypes of *PON1* rs662 and rs705379 genotypes was not statistically significant. Nevertheless, rs854560 genotypes showed statistically significant differences in arylesterase activities before intervention ( $p = .037$ ).

### 3.2. Association of PON1 polymorphisms with metabolic syndrome

*PON1*rs662, rs854560 and rs705379 genotypes were in Hardy-Weinberg equilibrium in cases and controls and in total studied population ( $p$ -value  $> 0.05$ ). *CETP* rs5882 genotypes in controls and studied population were in Hardy-Weinberg equilibrium ( $p$ -value  $> .05$ ) but in cases genotypes were not in Hardy-Weinberg equilibrium ( $p$ -value = .035).

The difference of allele and genotype frequencies of *PON1*rs662, rs854560 and rs705379 polymorphisms between cases and controls was not statistically significant ( $p$ -value  $> .05$ ). The Odds ratio estimated for the risky alleles for *PON1*rs662, rs854560 and rs705379 were not statistically significant ( $p$ -value  $> .05$ ). There was however a statistically significant difference in genotypes frequencies between cases and controls in *CETP* rs5882 ( $p$ -value = .034). The estimated odds ratio was statistically significant in the dominant model OR (95%CI) = 0.48 (0.25–0.92).

### 3.3. Haplotype analysis in the studied population

Haplotype frequencies of *PON1* desired polymorphisms in cases, controls and the whole population were estimated by PHASE software.

The  $p$ -value was estimated as 0.08 and showed that there was no statistically significant difference in haplotype distribution between cases and controls.

## 4. Discussion

Early diagnosis and treatment of the MetS can be one strategy to prevent cardiovascular disease and type 2 diabetes mellitus.

**Table 3**  
The relationship of PON1 polymorphisms with arylesterase activity.

SNP	Variable	Median	Percentile		P-value
			25th	75th	
rs662	arylesterase	145.54	89.05	206.106	0.331
rs854560	arylesterase	149.109	89.05	206.106	<b>0.037*</b>
rs854560	Average Activity	156.87	89.05	206.106	<b>0.035*</b>
rs705379	arylesterase	141.47	89.05	206.106	0.425

The results of arylesterase activity of rs662 and rs705379 genotypes before intervention was shown that these were not statistically significant. The results of arylesterase activity of rs854560 genotypes was shown that before intervention and the average activities were significant. Comparisons are performed using Kruskal-Wallis test. Statistical significance level P-value < .05.

**Table 4**  
Genotype Frequency distribution of PON1rs662 of the study subjects.

Study Group (No.)	Genotypes			p-value	Alleles		p-value	OR(95%CI)	p-value
	N(%)	N(%)	N(%)		N(%)	N(%)			
<i>PON1rs662</i>	AA	AG	GG	0.15	A	G	0.09	1.46(0.94–2.30)	0.09
Case (79)	27(34.2)	42(53.2)	10(12.7)		96(60.75)	62(39.24)			
Control (100)	44(48.9)	37(41.1)	9(10)		125(69.44)	55(30.55)			
<i>PON1rs854560</i>	AA	AT	TT	0.93	A	T	1	1(0.65–1.55)	1
Case (80)	31(38.8)	42(52.5)	7(8.8)		104(65)	56(35)			
Control (100)	40(40)	50(50)	10 (10)		130(65)	70(35)			
<i>PON1rs705379</i>	CC	CT	TT	0.28	C	T	0.13	1.38(0.90–2.11)	0.13
Case (77)	17(22.1)	43(55.8)	17(22.1)		77(50)	77(50)			
Control (100)	32(32)	52(52)	16(16)		116(58)	84(42)			
<i>CETPrs5882</i>	AA	AG	GG	0.34	A	G	0.24	1.29(0.84–1.97)	0.24
Case (79)	20(25.3)	50(63.3)	9(11.4)		90(56.96)	68(43.03)			
Control (100)	41(41)	44(44)	15(15)		126(63)	74(37)			
<sup>†</sup> Dominant model	AA	AG + GG						0.48(0.25–0.92)	0.029 [0.1]*

Comparisons are performed using the  $\chi^2$  test. Statistical significance level P-value < .05. \*p-value after Bonferroni correction (multiple testing). The odds ratio was of Statistical significance for *CETPrs5882* in the dominant model. All other models were analysed for odds ratio however there was no significant difference (data has only been shown for the Multiplicative model for *PON1rs662*, *rs854560*, and *rs705379*).

**Table 5**  
Haplotype frequencies in Case, Control and studied population.

Haplotype	Total	Case	Control
111 (CAA)	0.303	0.298	0.307
112(CAG)	0.141	0.139	0.143
121 (CTA)	0.087	0.051	0.116
112 (CTG)	0.013	0.013	0.012
211 (TAA)	0.068	0.054	0.079
212 (TAG)	0.136	0.157	0.119
221 (TTA)	0.194	0.203	0.188
222 (TTG)	0.055	0.082	0.033

P-value for testing H0: Cases ~ Controls = 0.08, Statistical significance level P-value < .05.

Due to the complexity and uncertainties about this concept a comprehensive understanding of the underlying pathophysiology leading to the disease is required and genetic studies may be useful.

Our findings revealed that there was no association between *PON1rs662*, *rs854560* and *rs705379* and MetS.

One similar study has been conducted in the south-east of Iran in which it was reported that there was an association between the *PON1* polymorphisms and the risk of MetS. For *PON1rs662*, carriers of AG + GG and GG genotypes had an increased risk of MetS. However, the calculated risk for *rs854560* and *rs705379* was not statistically significant [23].

The different results of the two studies may be due to different sample sizes, allele frequencies and life styles (different Iranian minorities) which may therefore influence the risk of MetS. Moreover because of the lack of Hardy-Weinberg analysis, the interpretation of these results may be difficult. Allele frequencies of *PON1*

polymorphisms have shown widely different distributions among populations. In the South-east of Iran, the minor allelic frequency of *PON1rs662* is 32%, *rs854560* is 50% and *rs705379* is 32% in healthy individuals [23] while in our study, they were 30.55%, 35% and 42% respectively. Only allele frequencies of the *PON1rs662* was similar in these two populations. In our study population, the frequency of *rs662* allele A was 69.44% and G 30.55% similar to the South-east of Iran that had allele A 68% and G 32% frequent. Whereas, *rs854560* both alleles, A and T were 50% frequent and *rs705379* allele C 68% and T 32% frequent in the South-east of Iran. In our population, they were: A 65% and T 35% for *rs854560* and C 58% and T 42% for *rs705379*.

The allele distribution of *rs662* and *rs854560* in our population is similar to that reported in a study based in Spain (*rs662* = 0.30%, *rs854560* = 0.37%, *rs705379* = 0.54%) [24] and to an Italian study where *rs662*, *rs854560* and *rs705379* allele frequencies have been reported as 0.35%, 0.34%, 0.43% respectively [11]. In our study the minor allele frequencies of the *PON1rs854560* T allele was estimated as 35% in both cases and controls.

Other oxidative stress related conditions like cardiovascular diseases, Alzheimer's and cancer have also shown various prevalence and results of association with *PON1* polymorphisms in different ethnicities based on various studies [7]. Also, it is demonstrated that genetic confounding or population stratification effects explain contradiction of association studies [25].

We have also found that there was no significant difference among genotypes of each *PON1* polymorphisms in serum paraoxonase activity. Possible reasons for this result may be due to a small sample size, as when considering the means of enzyme paraoxonase activities there is a difference but it was not

statistically significant. There was an association between arylesterase activity and *PON1*rs854560 but not with rs662 and rs705379. The mean arylesterase activities of AG genotypes of rs85450 was higher than other genotypes which may be due to the number of heterozygotes that was higher in this studied population or that this genotype is in linkage disequilibrium with allele C of rs705379 that shows a higher concentration and enzyme arylesterase activity.

In the present study, we found that there was no association between haplotypes of the *PON1* polymorphisms and the presence of MetS in this population.

Most of the association studies of haplotypes of *PON1* polymorphisms are focused on obesity, and their relationship with metabolic syndrome have not been assessed independently [26–28].

We found a weak association between *CETP*rs5882 polymorphism and MetS. In our population two copies of allele A had a protective effect. However, after Bonferroni correction this was not significant.

Studies similar to our research have not been carried out. Few studies have demonstrated positive association of CETP level and obesity [29–31].

In various studies, the frequency of I405V alleles has been reported differently due to differences in sample size, ethnic groups and geographical places. However in every source, allele G has been known as a minor allele with 25% frequency [32]. The frequency of allele G was 0.37% in our population. It was 0.35% in Azerbaijan, almost similar to the Caucasian population with 32 [33] in Ahvaz (the south-west of Iran) it was 0.37 [34] and Tehran 0.36% [35]. It was 0.617 in Asia and 0.611 in the African-American population [36].

In this study, there was no significant difference in CETP levels between genotypes. The protein level was measured in patients but was not done in controls.

Some studies have considered VV genotype as a risk factor for CHD [36] while others mentioned it as a protective effect against CAD [37].

It was thought that because CETP increases LDL level and decreases HDL-c, it may have a destructive effect on the heart and arteries despite the fact that the use of CETP inhibitor drugs increased stroke in patients in phase 3 clinical trials [37]. Therefore this protein cannot have a simple and direct relationship with lipid profile and risk of the diseases, and so more studies are essential. This result is consistent with previous studies reporting no association between certain genetic variants (e.g. TNF- $\alpha$  G-308A polymorphism) and the presence of Met.S [38].

The full explanation of the results of the randomised clinical trial study is not in the scope of our study. However, the non-significant results of the effect of genotypes on *PON1* enzymatic activities and CETP concentrations is possibly due to insufficient sample size, the influence of life style, ethnicity or biochemical factors (HDL-c, TG, cholesterol) on enzymes.

## 5. Conclusions

In conclusion, we could not find any association between *PON1* rs662, rs854560 and rs705379 genotypes and haplotypes with the risk of metabolic syndrome. However we found an association between *CETP* rs5882 genotypes and the presence of metabolic syndrome. Also having two A allele for *CETP* rs5882 may confer some degrees of protection. Moreover, it seems that neither CETP concentration nor *PON1* activity may be affected by the genotype in this study.

Curcumin supplementation had no considerable effects on *PON1* Paraoxonase/Arylesterase activity and CETP protein levels among three groups of MetS patients (1-phytosomal Curcumin, 2-plain curcumin and 3-placebo) before and after intervention.

## Acknowledgment

The authors frankly thank all of the patients and their family members who volunteered to participate in this study. We are also particularly grateful to the Research Council of the Mashhad University of Medical Sciences (MUMS) for the financial support of the study (Grant no. 931533).

## References

- [1] Huang PL. A comprehensive definition for metabolic syndrome. *Dis Models Mech* 2009;2(5–6):231–7.
- [2] Peters C. Metabolic syndrome—a literature review, a report submitted to the faculty of the college of nursing in partial fulfillment of the requirements for the degree of master of nursing in the Graduate College The University of Arizona 2007 (2007):1–85.
- [3] Berenji S, Rahmat AB, Hanachi P, Sunn LM, Yassin ZB, Sahebamee F. Metabolic syndrome in Iran. *Global J Health Sci* 2010;2(2):117–22.
- [4] Stančáková A, Laakso M. Genetics of metabolic syndrome. *Rev Endocr Metabol Disord* 2014;15(4):243–52.
- [5] Bellia A, Giardina E, Lauro D, Tesaro M, Di Fede G, Cusumano G, et al. “The Linosa Study”: epidemiological and heritability data of the metabolic syndrome in a Caucasian genetic isolate. *Nutr Metab Cardiovasc Dis* 2009;19(7):455–61.
- [6] Lin H-F, Boden-Albala B, Juo S, Park N, Rundek T, Sacco R. Heritabilities of the metabolic syndrome and its components in the Northern Manhattan Family Study. *Diabetologia* 2005;48(10):2006–12.
- [7] She ZG, Chen HZ, Yan Y, Li H, Liu DP. The human paraoxonase gene cluster as a target in the treatment of atherosclerosis. *Antioxid Redox Signal* 2012;16(6):597–632.
- [8] Akbarzadeh M, Hassanzadeh T, Saidijam M, Esmaeili R, Borzouei S, Hajilooi M, et al. Cholesteryl ester transfer protein (CETP) –629C/A polymorphism and its effects on the serum lipid levels in metabolic syndrome patients. *Mol Biol Rep* 2012;39(10):9529–34.
- [9] Povel CM, Boer JM, Reiling E, Feskens EJ. Genetic variants and the metabolic syndrome: a systematic review. *Obes Rev* 2011;12(11):952–67.
- [10] Costa LG, Vitalone A, Cole TB, Furlong CE. Modulation of paraoxonase (*PON1*) activity. *Biochem Pharmacol* 2005;69(4):541–50.
- [11] Imai Y, Morita H, Kurihara H, Sugiyama T, Kato N, Ebihara Shindo A, et al. Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. *Atherosclerosis* 2000;149(2):435–42.
- [12] Adkins S, Gan K, Mody M, La Du B. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. *Am J Hum Genet* 1993;52(3):598.
- [13] Martinelli N, Micaglio R, Consoli L, Guarini P, Grison E, Pizzolo F, et al. Low levels of serum paraoxonase activities are characteristic of metabolic syndrome and may influence the metabolic-syndrome-related risk of coronary artery disease. *Exp Diabetes Res* 2012;2012:231502.
- [14] Puppala S, Dodd GD, Fowler S, Arya R, Schneider J, Farook VS, et al. A genomewide search finds major susceptibility loci for gallbladder disease on chromosome 1 in Mexican Americans. *Am J Hum Genet* 2006;78(3):377–92.
- [15] Rühling K, Lang A, Richard F, Van Tol A, Eisele B, Herzberg V, et al. Net mass transfer of plasma cholesteryl esters and lipid transfer proteins in normolipidemic patients with peripheral vascular disease. *Metabolism* 1999;48(11):1361–6.
- [16] Tall AR. Plasma cholesteryl ester transfer protein. *J Lipid Res* 1993;34(8):1255–74.
- [17] Weber O, Bischoff H, Schmeck C, Bottcher MF. Cholesteryl ester transfer protein and its inhibition. *Cell Mol Life Sci* 2010;67(18):3139–49.
- [18] Peloso GM, Demissie S, Collins D, Mirel DB, Gabriel SB, Cupples LA, et al. Common genetic variation in multiple metabolic pathways influences susceptibility to low HDL-cholesterol and coronary heart disease. *J Lipid Res*. 2010;51(12):3524–32.
- [19] Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of *Curcuma longa*: a review of preclinical and clinical research. *Altern Med Rev* 2009;14(2):141–53.
- [20] Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. *Mol Pharm* 2007;4(6):807–18.
- [21] Choubey A. Phytosome: a novel approach for herbal drug delivery. *Int J Pharm Sci Res* 2011;2(4):807.
- [22] D’Amelio M, Ricci I, Sacco R, Liu X, D’Agruma L, Muscarella LA, et al. Paraoxonase gene variants are associated with autism in North America, but not in Italy: possible regional specificity in gene-environment interactions. *Mol Psychiatry* 2005;10(11):1006–16.
- [23] Kordi-Tamandani DM, Hashemi M, Sharifi N, Kaykhaei MA, Torkamanzehi A. Association between paraoxonase-1 gene polymorphisms and risk of metabolic syndrome. *Mol Biol Rep* 2012;39(2):937–43.
- [24] Ko YL, Ko YS, Wang SM, Hsu LA, Chang CJ, Chu PH, et al. The Gln-Arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan. *Atherosclerosis* 1998;141(2):259–64.
- [25] Huen K, Harley K, Beckman K, Eskenazi B, Holland N. Associations of *PON1* and genetic ancestry with obesity in early childhood. *PLoS ONE* 2013;8(5):e62565.

- [26] Chen J, Chan W, Wallenstein S, Berkowitz G, Wetmur JG. Haplotype-phenotype relationships of paraoxonase-1. *Cancer Epidemiol Biomark Prev* 2005;14(3):731–4.
- [27] Ferré N, Feliu A, García-Heredia A, Marsillach J, París N, Zaragoza-Jordana M, et al. Impaired paraoxonase-1 status in obese children. Relationships with insulin resistance and metabolic syndrome. *Clin Biochem* 2013;46(18):1830–6.
- [28] Jarvik GP, Hatsukami TS, Carlson C, Richter RJ, Jampsa R, Brophy VH, et al. Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. *Arterioscler Thromb Vasc Biol* 2003;23(8):1465–71.
- [29] Arai T, Yamashita S, Hirano K-I, Sakai N, Kotani K, Fujioka S, et al. Increased plasma cholesteryl ester transfer protein in obese subjects. A possible mechanism for the reduction of serum HDL cholesterol levels in obesity. *Arterioscler Thromb Vasc Biol* 1994;14(7):1129–36.
- [30] Asayama K, Hayashibe H, Dobashi K, Uchida N, Nakane T, Kodera K, et al. Increased serum cholesteryl ester transfer protein in obese children. *Obes Res* 2002;10(6):439–46.
- [31] Dullaart R, Sluiter W, Dikkeschei L, Hoogenberg K, Tol A. Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism. *Eur J Clin Invest* 1994;24(3):188–94.
- [32] Boekholdt SM, Thompson JF. Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease. *J. Lipid Res.* 2003;44(6):1080–93.
- [33] Ghatreh Samani K, Noori M, Rohbani Nobar M, Hashemzadeh Chaleshtori M, Farrokhi E, Darabi Amin M. I405V and –629C/A polymorphisms of the cholesteryl ester transfer protein gene in patients with coronary artery disease. *Iran Biomed J* 2009;13(2):103–8.
- [34] Karimpour F, Mohammadzadeh G, Kheirollah A, Ghaffari MA, Saki A. Association of I405V polymorphism of cholesteryl ester transfer protein gene with coronary artery disease in men with type 2 diabetes. *ARYA Atheroscler* 2016;12(2):68–75.
- [35] Goodarzynejad H, Boroumand M, Behmanesh M, Ziaee S, Jalali A. Cholesteryl ester transfer protein gene polymorphism (I405V) and premature coronary artery disease in an Iranian population. *Bosnian J Basic Med Sci* 2016;16(2):114–20.
- [36] Isaacs A, Sayed-Tabatabaei FA, Hofman A, Oostra BA, Klungel OH, Maitland-vander Zee A-H, et al. The cholesteryl ester transfer protein I405V polymorphism is associated with increased high-density lipoprotein levels and decreased risk of myocardial infarction: the Rotterdam Study. *Eur J Cardiovasc Prev Rehabil* 2007;14(3):419–21.
- [37] Cappel DA. *Metabolic health with obesity: a novel role for cholesteryl ester transfer protein.* Vanderbilt University; 2014.
- [38] Mirhafez SR, Avan A, Pasdar A, Kazemi E, Ghasemi F, Tajbakhsh A, Tabaei S, Ferns GA, Ghayour-Mobarhan M. Association of tumor necrosis factor- $\alpha$  promoter G-308A gene polymorphism with increased triglyceride level of subjects with metabolic syndrome. *Gene* 2015;568(1):81–4.